Asset profile
Thalidomide
Small molecule
Evidence outlook
Approved: Multiple Myeloma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
67 competitors in this universe: 7 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Thalidomide: this drug | Approved | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Lenalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Thalidomide Analog | ||
| Pomalidomide | Approved | Small molecule | Cereblon E3 ubiquitin-ligase, Cereblon (CRBN) | ||
| Iberdomide | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Mezigdomide | Phase 3 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Cemsidomide | Phase 2 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| ICP-490 | Phase 1/2 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| TQB3820 | Phase 1 | Small molecule | Cereblon E3 ubiquitin-ligase | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Bortezomib | Approved | Small molecule | Proteasome | ||
| Carfilzomib | Approved | Small molecule | Proteasome | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Daratumumab | Approved | Monoclonal antibody | CD38 | ||
| Denosumab | Approved | Monoclonal antibody | RANKL | ||
| Elotuzumab | Approved | Monoclonal antibody | SLAMF7 (CS1/CD319) | ||
| Elranatamab | Approved | Multispecific antibody | BCMA x CD3 |
…and 52 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
1 further head-to-head pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(17 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2027 (12)
February 2027 (2)
March 2027 (1)
What to watch
April 2027 (1)
What to watch
June 2027 (1)
What to watch
August 2027 (2)
October 2027 (2)
December 2027 (3)
What to watch
What to watch
What to watch
2028 (2)
2029 (1)
June 2029 (1)
What to watch
2030 (2)
April 2030 (1)
What to watch
June 2030 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.